Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented…
Highly experienced biopharma executive Dr Cristina Csimma joins Asgard's Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof…
NASHVILLE, Tenn. and SAN ANTONIO, June 2, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform empowering independent oncology practices, and…
Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical…
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed…
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)…
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver…
David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1,…
SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for…
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology…